Patent: 9,416,371
✉ Email this page to a colleague
Summary for Patent: 9,416,371
Title: | T-cell vaccination with viral vectors via mechanical epidermal disruption |
Abstract: | Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer. |
Inventor(s): | Kupper; Thomas S. (Weston, MA), Liu; Luzheng Lisa (Vernon Hills, IL), Clark; Rachel A. (Belmont, MA) |
Assignee: | TremRx, Inc. (Boston, MA) |
Application Number: | 14/165,126 |
Patent Claims: | see list of patent claims |
Details for Patent 9,416,371
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Emergent Biodefense Operations Lansing Llc | BIOTHRAX | anthrax vaccine adsorbed | Injection | 103821 | 11/12/1998 | ⤷ Try a Trial | 2028-10-31 |
Emergent Product Development Gaithersburg, Inc. | ACAM2000 | smallpox (vaccinia) vaccine, live | For Injection | 125158 | 08/31/2007 | ⤷ Try a Trial | 2028-10-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |